Cristina Gasparetto

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Current Appointments & Affiliations

Professor of Medicine · 2018 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine

Member of the Duke Cancer Institute · 1993 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Conference Blood · November 3, 2025 AbstractIntroduction: Cytokine release syndrome (CRS) is a systemic inflammatory condition seen in 50-80% of patients after bispecific T ce ... Full text Cite

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Conference Blood · November 3, 2025 AbstractBackground Translocation of chromosomes 4 and 14 (t(4;14)) results in overexpression of MMSET and has been associated with poor cli ... Full text Cite

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Conference Blood · November 3, 2025 AbstractBackground: A single nucleotide polymorphism (SNP) in ACKR1/DARC results in erythrocyte Duffy null phenotype in ~66% of African Ame ... Full text Cite

View All Publications

Recent Grants

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4

Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030

Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029

View All Grants

Education, Training & Certifications

Sapienza University of Rome (Italy) · 1986 M.D.